Lipocine Inc LPCN

NAS: LPCN | ISIN: US53630X1046   30/04/2025
3,310 USD (+1,53%)
(+1,53%)   30/04/2025

26 maart 2025 · Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 · Persbericht

13 maart 2025 · Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 · Persbericht

12 maart 2025 · Lipocine Announces FDA Labeling Changes for Testosterone Products · Persbericht

5 september 2024 · Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® · Persbericht

27 augustus 2024 · Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

8 augustus 2024 · Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 · Persbericht

25 juni 2024 · Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study · Persbericht

10 juni 2024 · Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 · Persbericht

9 mei 2024 · Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 · Persbericht

8 mei 2024 · Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 · Persbericht

1 mei 2024 · Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 · Persbericht

11 april 2024 · Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity · Persbericht

28 maart 2024 · Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis · Persbericht

25 maart 2024 · Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 · Persbericht

7 maart 2024 · Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 · Persbericht

6 maart 2024 · Lipocine to Present at 36th Annual Roth Conference · Persbericht

6 februari 2024 · Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 · Persbericht

2 februari 2024 · Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals · Persbericht

18 januari 2024 · Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada · Persbericht

19 december 2023 · Lipocine to Present at Biotech Showcase 2024 · Persbericht

Mijn selecties